Odyssey Therapeutics, Inc. — Investor Relations & Filings

Odyssey Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming the standard of care for patients with autoimmune and inflammatory diseases. The company discovers, develops, and commercializes next-generation immunomodulators by targeting upstream signaling nodes and mechanisms, such as those in the innate immune system. This approach aims to prevent pathological inflammation before it occurs, differentiating it from existing therapies that address downstream responses. Odyssey Therapeutics seeks to induce long-lasting, deep remission with potentially less immunosuppressive risk. Leveraging a replicable drug development model and expertise in immunobiology, medicinal and computational chemistry, protein biochemistry, structural biology, genetics, and pharmacology, the company advances a pipeline of small molecule and protein therapeutics, including OD-07656, for conditions with significant unmet medical needs.